Technology Partnerships

BioInvent has entered into several partnerships around the development of antibodies.

Antibody development partnerships typically involve BioInvent utilising its proprietary n-CoDeR^® technology to identify antibodies that can bind to partners' selected targets. Selected antibodies are further developed either by the partner alone or as part of a continued collaboration with BioInvent. BioInvent receives milestone payments and royalties on sales from these projects.  Partners to date include Bayer, Daiichi Sankyo, and Mitsubishi Tanabe.

Bayer HealthCare (www.bayer.co.uk)
Discovery and development of antibody products using the n-CoDeR^® library. The agreement allows for up to 14 therapeutic antibody products to be developed.

Daiichi Sankyo Company (http://www.daiichisankyo.com/)
Licence and discovery agreement for the development of therapeutic antibodies against multiple targets, using the n-CoDeR^® library. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.

Mitsubishi Tanabe (www.mt-pharma.co.jp)
Discovery and development of antibody products using the n-CoDeR^® library. The agreement allows for up to five therapeutic antibody products to be developed.

XOMA (www.xoma.com)
Cross-license agreement for antibody related technologies, including the n-CoDeR^® platform.